SILICO ORGANICO

Silico Organico is a metalloid which intervenes in the structures of mineral and organic compounds. Its lack implies the destructuring of connective tissue, while its intake permits the regeneration or irregular tissue.

FORMAT: 5 and 10ml phials, 0.5%

QUALITATIVE COMPOSITION: Monomethyl trisilanol manorunate,
Excipients c.s.

PROPERTIES: Organic silico is one of the most widely used medications in Mesotherapy, where it has wide-ranging indications in processes as important as facial ageing and cellulites.

Silanoles, biologically active, water-soluble, organic compounds of silica, are employed for rejuvenating purposes. Their action mechanism is increasing the cellular concentration of the second cAMP messenger by stimulating the formation of adenyl cyclase.

Among the physiological actions attributed to the silanoles which can be clinically exploited, the following are emphasised:

• It is structural component of the connective tissue, forming part of important macro-molecules as elastin, collagen, the proteoglycans and structural glycoproteins (Carlislie and Schwartz). At this tissue level it induces the control and proliferation of fibroblasts, and favours the regeneration of elastic and callagenous fibres.
• Indispensable for the normal development of the entire individual. A high percentage is found in embryonic mesenchyma and decreases in the course of ageing, contributin to tissue sclerosis.
• Organic silica acts as a regulator of cellular metabolisms and cell division.
• It is a metabolic protector acting along different fronts (it combats the lipid peroxidation responsible for the release of free radicals, it combats the non-enzymatic glycosidation of the proteins making up connective tissue, prevents the destruction of macro-molecules, stimulates and regulates fibroblast mitosis, from which its role in the regeneration of epidermic and dermic cells is inferred).

PROCAINE

The Procaine used in Mesotherapy comes in the form of 1% or 2% Procaine hydrochloride, with a molecular weight of 272.8 and a pH of between 5 and 6.

Procaine, which is lipo-soluble, is endowed with quick reabsorption through the membranes, but has difficulty in crossing into epithelia, making it a mediocre local anaesthetic.

It is acetylated at the level of the liver and then very quickly hydrolysed in plasma by a pseudo-choline-esterase in diethylaminoethanol and p-amino benzoic acid, responsible for the allergies caused by its ”para” group.

The normal dosage for Procaine for general administration is 2 to 3 mg per kg of body weight. For example, 120 to 180 mg for an adult weighing 60 kg. Intradermally, the quantity administered is in the order of 20 mg, i.e. 6 to 9 times less.

Format: Phials, 1% and 2%

Qualitative composition: Procaine, Excipient c.s.

Properties of the product:

• Local anaesthetic activity: its effect is short lasting due to the stabilising action of the membrane which fights the transmembrane ionic migration.

• Action on the cardiovascular system, antiarrhytmic on the heart and vasodilatory on the blood vessels.

• Action on the autonomous nervous system: at strong doses, Procaine produces ganglioplegic effects due to the inhibition of the ganglion receptors.

• Action on the C.N.S.: at small doses, accelerated rhythm and increased amplitude of respiration; at strong doses, depression of the respiratory centre.

• Action on ageing: tissue regeneration due to stimulation of DNA synthesis for some, controversial results for others.

• Haemorrheological action: decreased rigidity of the red corpuscles and improved ability to change shape.

Effects and indications

• Local anaesthetic
• In cellulites, combined with other preparations or substances such as Sodium heparin + Procaine, Chlorproethacin, Thiomucase, etc.

SECONDARY EFFECTS

• Exceptionally, hypersensitivity reactions: allergic dermatitis, asthmatic attacks, anaphylactic shock and even fatal collapse. Perform an intradermal Procaine sensitivity test on all patients that are about to be subjected to this treatment.
• Nausea, vomiting, irritability, unease (reduce the speed of the drip); abandon treatment if symptoms persist.

PRECAUTIONS

• Complete incompatibility with sulphamide treatments.
• Do not administer in the event of epileptic precedents.

LIPOLITICAS
(ARTICHOKE EXTRACT - CYNARA SCOLYMUS)

FORMAT: 5ml phials of 2% purified Cynara Scolymus extract

QUALITATIVE COMPOSITION: Purified extract of the juice of fresh artichoke leaves, Excipient c.s.

PROPERTIES OF THE PRODUCT:

1. Choleretic action: increases the volume of excreted bile.
2. Action on the antitoxic function of the liver.
3. Action on the glycogenic function of the liver.
4. Action on the metabolism of lipids.
5. Action on the kidney and the metabolism of urea: increased diuresis and kidney urea-concentration, and stimulation of liver urogenesis.
6. Action on the metabolism of cholesterol.

EFFECTS AND INDICATIONS:

• Choleric herbal therapy in liver-bile insufficiency
• Symptomatic treatment of dyspeptic irregularities
• Renal elimination of water
• Excess urea in the blood: complementary treatment of urinary lithiasis
• Hypercholesterolaemia
• Cellulites

MESOTHERAPEUTIC COMMENTARIES
Cynarin, the active ingredient, is well known in Mesotherapy and was proposed by Bartoletti, in 1971, for treating cellulites. In 1972, Legrand emphasised its mildly diuretic and hepato-detoxifying role. Its choleretic action aids the treatment of essential constipation. In addition to these actions, it exercises a certain control on lipolysis, favouring the synthesis energy-transporting enzymes (NAD-NADH2 and NADP-NADPH2).

L-CARNITINE

FORMAT: 5ml phials, containing 1g of L-Carnitine

QUALITATIVE COMPOSITION: L-Carnitine, Excipient c.s.

PROPERTIES OF THE PRODUCT: Diminishes the bioavailability of fatty acids and the glycerol released during the lipolytic process.

ACTION MECHANISM: During the lipolysis process, the triglycerides breakdown into two fractions: the glycerolated fraction (which may pass into the blood circulation or incorporate itself into the monophosphate shunt at the hepatic level) and the fatty acids, which have two main destinations, the blood circulation in the form of NEFA, or they are activated by esterification with the acetyl-coenzyme-A. Some of these activated fatty acids will be oxidised, while others are reused in the formation of new triglycerides.

Esterified fatty acids have a limited capacity to penetrate inside the mitochondrion and require a physiological carrier to perform this passage. This transported in carnitine. Once inside the mitochondrion, it transfers the fatty acids and the acetyl-CoA of the fatty acids for oxidation by specific enzymes and then returns to the cellular cytosol to perform the process again. In this way, with the aid of carnitine, the activated fatty acids are diverted towards oxidation and are not employed in the neoformation of TGC and, therefore, there is less cytoplasmatic bioavailability of activated fatty acids. For this reason, the name of “fat devouring molecule” given to L-Carnitine is not strictly true, it being more realistic to use the term “fatty acid transporting molecule”.

However, in addition, carnitine halts the rate of glycolisis by reducing an intermediate metabolite of the glycolic sequence and the level of glycerol-3-P. Therefore, carnitine reduces both precursors necessary of the de novo synthesis of TGC.

Because of its action mechanism, it is easy to understand that this is not a lipolytic medication, but an adjuvant to medications that do posses lipolytic action by increasing the intra-adipocytary levels of cAMP.